Myeloid Therapeutics and MaxCyte Enter Clinical and Commercial Licensing Agreement to Advance Myeloid’s Cell Therapy Programs
Myeloid to utilize MaxCyte’s Flow Electroporation® technology and [...]
CARMA Cell Therapies™ to Share Results of In-vitro Characterization of MCY-M11 at SITC 2020 Annual Meeting
Gaithersburg, Maryland – November 9, 2020: MaxCyte, Inc., a global [...]
MaxCyte to Present at Two Upcoming Virtual Healthcare Investor Conferences
GAITHERSBURG, MD, November 9, 2020 — MaxCyte, Inc., a [...]
MaxCyte Bolsters Leadership Team with Promotion of Brad Calvin to Chief Commercial Officer and New Key VP Appointments
Gaithersburg, Maryland – October 13, 2020: MaxCyte, Inc., a [...]
CARMA Cell Therapies™ Expands Phase I Trial of Anti-Mesothelin mRNA CAR-PBMC Cell Therapy MCY-M11
New parallel cohort will broaden evaluation of MCY-M11 in [...]
MaxCyte to Present at Upcoming 2020 H.C. Wainwright & Co 22nd Annual Global Investment Virtual Conference
Gaithersburg, Maryland – September 10, 2020: MaxCyte, a global [...]
MaxCyte Appoints Amanda L. Murphy as Chief Financial Officer and Names Ron Holtz as Senior Vice President & Chief Accounting Officer
Murphy brings a wealth of life sciences capital markets [...]
APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401
APEIRON to utilize MaxCyte’s ExPERT® platform for siRNA-based [...]
MaxCyte® Initiates Launch of New ExPERT™ Range of Expanded Research and GMP Grade Disposables for Complex Cellular Engineering
R-1000, a cuvette that can process up to 1 [...]
MaxCyte to Present at 2020 European Biotech Investor Day
Solebury Trout, Goodwin, Deutsche Bank and Nasdaq to present [...]